Antibody-drug conjugate · Cytotoxic, directed at CD79b · developed by Genentech
Polatuzumab vedotin is an antibody-drug conjugate that binds CD79b, a B-cell surface protein of the B-cell receptor, and delivers the anti-mitotic agent MMAE into the cell after internalization. MMAE binds microtubules, inhibiting cell division and inducing apoptosis. It is used in B-cell lymphoma, including diffuse large B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 24, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07917832 | Phase 2 | Multi Center | Not yet recruiting | BMY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B Cell LymphomaG2pGlofitamabGolcadomideMulti CenterPhase 2PolauzumabVedotin
Updated Nov 8, 2026.